Long-Term Follow-Up After Gene Therapy for Canavan Disease
Open accessThe DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Abstract
Gene therapy for Canavan disease results in a decrease in pathologically elevated N-acetyl-aspartate concentrations in the brain and long-term clinical stabilization.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AAV vector administration to the CNS has an excellent safety and efficacy profile.”
From AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease (2018) · cites this paper as [59]
Experimental — accuracy not yet measuredIn the citing paper
“The reversal of biochemical and structural biomarkers suggests that the process is reversible; however, earlier intervention is suspected to lead to a more robust clinical response.54”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [54]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Robust Locally Weighted Regression and Smoothing Scatterplots
Cleveland, W. S. (1979) · Journal of the American Statistical Association · doi:10.1080/01621459.1979.10481038 · Cited by 11,594 · cited 1×
“S2) and suggest a variable amount of regional and subject-specific stabilization (56).”
BackgroundRandom-Effects Models for Longitudinal Data
Laird, N. M., & Ware, J. H. (1982) · Biometrics · doi:10.2307/2529876 · Cited by 8,923 · cited 2×
“Inferences regarding changes in NAA concentrations were tested using the Wald statistic for posttreatment slope versus zero and the change from before treatment to after treatment (54).”
MethodTransplantation of Umbilical-Cord Blood in Babies with Infantile Krabbe's Disease
Escolar, M. L., Poe, M. D., Provenzale, J. M., Richards, K. C., Allison, J., Wood, S., Wenger, D. A., Pietryga, D., Wall, D., Champagne, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042604 · Cited by 709
Kreis, R., Ernst, T., & Ross, B. D. (1993) · Magnetic Resonance in Medicine · doi:10.1002/mrm.1910300405 · Cited by 681 · cited 1×
“Another group (62) measured quantitative NAA during development in 50 subjects from birth to 18 years, who were scanned for a variety of reasons, and found that NAA concentrations in occipital gray matter (where NAA is highest) asymptotically peaked around 4 years of age at about 8.”
BackgroundImmunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies
Simmons, M. L., Frondoza, C. G., & Coyle, J. T. (1991) · Neuroscience · doi:10.1016/0306-4522(91)90101-s · Cited by 626 · cited 1×
“It is found throughout the neuronal cytoplasm, dendrites, and axons (19, 20), where it normally forms a steep concentration gradient with respect to the extracellular space (21, 22).”
BackgroundUrenjak, J., Williams, S. R., Gadian, D. G., & Noble, M. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb08875.x · Cited by 503 · cited 1×
“In addition to high concentrations normally found within neurons, NAA is detected at lower concentrations in oligodendrocytes (24) during induction of ASPA expression during early postnatal development (25, 26).”
BackgroundHaley, S. M. (1998) · Medical Entomology and Zoology · Cited by 484
Cord-Blood Transplants from Unrelated Donors in Patients with Hurler's Syndrome
Staba, S. L., Escolar, M. L., Poe, M., Kim, Y., Martin, P. L., Szabolcs, P., Allison-Thacker, J., Wood, S., Wenger, D. A., Rubinstein, P., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032613 · Cited by 478
N -Acetylaspartate in neuropsychiatric disorders
Tsai, G., & Coyle, J. T. (1995) · Progress in Neurobiology · doi:10.1016/0301-0082(95)00014-m · Cited by 422 · cited 1×
“1% of the brain by weight (12, 13) and is involved in brain development and homeostasis (14).”
BackgroundAspartoacylase deficiency and N‐acetylaspartic aciduria in patients with canavan disease
Matalon, R., Michals, K., Sebesta, D., Deanching, M., Gashkoff, P., Casanova, J., Optiz, J. M., & Reynolds, J. F. (1988) · American Journal of Medical Genetics · doi:10.1002/ajmg.1320290234 · Cited by 404
Immunohistochemical localization of N-acetylaspartate in rat brain
Moffett, J. R., Aryan Namboodiri, M. A., Cangro, C. B., & Neale, J. H. (1991) · NeuroReport · doi:10.1097/00001756-199103000-00005 · Cited by 334
N-ACETYL-l-ASPARTIC ACID IN BRAIN
Tallan, H. H., Moore, S., & Stein, W. H. (1956) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)65789-8 · Cited by 325
Chakraborty, G., Mekala, P., Yahya, D., Wu, G., & Ledeen, R. W. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00456.x · Cited by 302
STUDIES ON THE DISTRIBUTION OF N-ACETYL-l-ASPARTIC ACID IN BRAIN
Tallan, H. H. (1957) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)65008-2 · Cited by 294 · cited 1×
“1% of the brain by weight (12, 13) and is involved in brain development and homeostasis (14).”
BackgroundPatel, T. B., & Clark, J. B. (1979) · Biochemical Journal · doi:10.1042/bj1840539 · Cited by 292
Janson, C., McPhee, S., Bilaniuk, L., Haselgrove, J., Testaiuti, M., Freese, A., Wang, D.-J., Shera, D., Hurh, P., Rupin, J., et al. (2002) · Human Gene Therapy · doi:10.1089/104303402760128612 · Cited by 255 · cited 31×
“Although unexpected, the transient rise in NAA observed at the time of initial administration of AAV2-ASPA was consistent with solute flux during brain osmoregulation and was fit using a ramp function.”
BackgroundMethodInfluentialSelf-citationParkin deletions in a family with adult-onset, tremor-dominant parkinsonism: Expanding the phenotype
Klein, C., Pramstaller, P. P., Kis, B., Page, C. E., Kann, M., Leung, J., Woodward, H., Castellan, C. C., Scherer, M., Vieregge, P., et al. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200007)48:1<65::aid-ana10>3.0.co;2-l · Cited by 243
Self-citationImmune responses to AAV in a phase I study for Canavan disease
McPhee, S. W. J., Janson, C. G., Li, C., Samulski, R. J., Camp, A. S., Francis, J., Shera, D., Lioutermann, L., Feely, M., Freese, A., et al. (2006) · The Journal of Gene Medicine · doi:10.1002/jgm.885 · Cited by 241 · cited 1×
“appeared limited and have been previously reported (59).”
BackgroundSelf-citationBaslow, M. H. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0750453.x · Cited by 240 · cited 5×
“The excitotoxic effects of NAA are still poorly understood in vivo and have been recently discounted (65), although NAA and NAAG were reported to activate N-methyl-D-aspartate (NMDA) receptors at millimolar concentrations (66, 67).”
BackgroundInfluentialCloning of the human aspartoacylase cDNA and a common missense mutation in Canavan disease
Kaul, R., Ping Gao, G., Balamurugan, K., & Matalon, R. (1993) · Nature Genetics · doi:10.1038/ng1093-118 · Cited by 221 · cited 1×
“Outside of the brain, aspartoacylase is present in peripheral tissues such as skin and kidney (3), but its only known role is the degradation of NAA in the brain.”
BackgroundMadhavarao, C. N., Arun, P., Moffett, J. R., Szucs, S., Surendran, S., Matalon, R., Garbern, J., Hristova, D., Johnson, A., Jiang, W., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409184102 · Cited by 212
Westbrook, G., Mayer, M., Namboodiri, M., & Neale, J. (1986) · The Journal of Neuroscience · doi:10.1523/jneurosci.06-11-03385.1986 · Cited by 181 · cited 1×
“The excitotoxic effects of NAA are still poorly understood in vivo and have been recently discounted (65), although NAA and NAAG were reported to activate N-methyl-D-aspartate (NMDA) receptors at millimolar concentrations (66, 67).”
BackgroundLeone, P., Janson, C. G., Bilianuk, L., Wang, Z., Sorgi, F., Huang, L., Matalon, R., Kaul, R., Zeng, Z., Freese, A., et al. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200007)48:1<27::aid-ana6>3.0.co;2-6 · Cited by 177 · cited 3×
“DNA)–ASPA] in 14 patients in 1999, which had suggested a partial reversal of elevated NAA concentrations (46, 47).”
BackgroundMethodSelf-citationXu, R., Janson, C., Mastakov, M., Lawlor, P., Young, D., Mouravlev, A., Fitzsimons, H., Choi, K.-L., Ma, H., Dragunow, M., et al. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301529 · Cited by 174 · cited 1×
“AAV2 was the safest and most effective gene transfer vector but is limited to expression of the therapeutic gene in neurons only (63).”
BackgroundSelf-citationD'Adamo, A. F., & Yatsu, F. M. (1966) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1966.tb10292.x · Cited by 162
Moreno, A., Ross, B. D., & Bluml, S. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.t01-1-00282.x · Cited by 152
Immunohistochemical localization of aspartoacylase in the rat central nervous system
Madhavarao, C. N., Moffett, J. R., Moore, R. A., Viola, R. E., Namboodiri, M. A. A., & Jacobowitz, D. M. (2004) · Journal of Comparative Neurology · doi:10.1002/cne.20080 · Cited by 146 · cited 1×
“progenitor (O2A) cells and oligodendrocytes in the brain (5–8), with smaller amounts in microglia and brainstem neurons (9).”
BackgroundAdachi, M., Schneck, L., Cara, J. F., & Volk, B. W. (1973) · Human Pathology · doi:10.1016/s0046-8177(73)80098-x · Cited by 143 · cited 1×
“Other reported abnormalities include misshapen mitochondria in swollen astrocytes (40), suggesting a metabolic imbalance.”
BackgroundBurri, R., Steffen, C., & Herschkowitz, N. (1991) · Developmental Neuroscience · doi:10.1159/000112191 · Cited by 137
Investigation into the Role of N‐Acetylaspartate in Cerebral Osmoregulation
Taylor, D. L., Davies, S. E. C., Obrenovitch, T. P., Doheny, M. H., Patsalos, P. N., Clark, J. B., & Symon, L. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.65010275.x · Cited by 136 · cited 1×
“Evidence to date suggests that the pathological effects of globally elevated NAA in Canavan disease are multifactorial and are related to its diverse physiological roles as an organic osmolyte (21, 27), water cotransporter in metabolically active cells (28), myelin precursor (7, 25, 29–33), intermediate for NAAG (34,…”
BackgroundCharacterization of the N‐acetylaspartate biosynthetic enzyme from rat brain
Madhavarao, C. N., Chinopoulos, C., Chandrasekaran, K., & Namboodiri, M. A. A. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01905.x · Cited by 134
Hagenfeldt, L., Bollgren, I., & Venizelos, N. (1987) · Journal of Inherited Metabolic Disease · doi:10.1007/bf01800038 · Cited by 121
In vivo quantitative proton MRSI study of brain development from childhood to adolescence
Horská, A., Kaufmann, W. E., Brant, L. J., Naidu, S., Harris, J. C., & Barker, P. B. (2002) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.10057 · Cited by 117 · cited 1×
“Another quantitative metabolite study (61) looking at multiple brain regions in normal pediatric subjects examined 15 subjects, aged 3 months through 19 years, and found a mean NAA concentration of 7.”
BackgroundKitada, K., Akimitsu, T., Shigematsu, Y., Kondo, A., Maihara, T., Yokoi, N., Kuramoto, T., Sasa, M., & Serikawa, T. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0742512.x · Cited by 112 · cited 2×
“NAA in extracellular fluid or cerebrospinal fluid (CSF) is associated with seizures in both humans and the tremor rat model of Canavan disease (41, 42).”
BackgroundPurification, Characterization, and Localization of Aspartoacylase from Bovine Brain
Kaul, R., Casanova, J., Johnson, A. B., Tang, P., & Matalon, R. (1991) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1991.tb02571.x · Cited by 109
Absence of N‐acetylaspartate in the human brain: Impact on neurospectroscopy?
Martin, E., Capone, A., Schneider, J., Hennig, J., & Thiel, T. (2001) · Annals of Neurology · doi:10.1002/ana.102.abs · Cited by 106 · cited 1×
“NAA is not absolutely necessary for myelination, and a case study of a child without any NAA showed only moderately delayed myelination (70).”
BackgroundBaslow, M. H., Suckow, R. F., Sapirstein, V. S., & Hungund, B. L. (1999) · Journal of Molecular Neuroscience · doi:10.1385/jmn:13:1-2:47 · Cited by 99
The Clinical Course of Canavan Disease
Traeger, E., & Rapin, I. (1998) · Pediatric Neurology · doi:10.1016/s0887-8994(97)00185-9 · Cited by 87 · cited 1×
“However, this classification is now viewed as flawed (43) with recommendations to use a gene-based diagnosis of typical versus mild Canavan disease instead.”
MethodHuang, W. Y., Wang, H., Kekuda, R., Fei, Y.-J., Friedrich, A., Wang, J., Conway, S. J., Cameron, R. S., Leibach, F. H., & Ganapathy, V. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38914-1 · Cited by 84 · cited 1×
“NAA and a related dipeptide N-acetyl-aspartyl-glutamate (NAAG) are transported from the cytoplasm to the extracellular space by an unidentified transporter, and NAA is taken up by glia through a dicarboxylic acid transporter (23) before hydrolysis by aspartoacylase.”
BackgroundN-Acetylaspartate synthase is bimodally expressed in microsomes and mitochondria of brain
Lu, Z., Chakraborty, G., Ledeen, R. W., Yahya, D., & Wu, G. (2004) · Molecular Brain Research · doi:10.1016/j.molbrainres.2003.12.002 · Cited by 82
Janson, C., McPhee, S., Francis, J., Shera, D., Assadi, M., Freese, A., Hurh, P., Haselgrove, J., Wang, D., Bilaniuk, L., et al. (2006) · Neuropediatrics · doi:10.1055/s-2006-924734 · Cited by 82 · cited 10×
“The reference ranges provided for each region (yellow shading) are 95% confidence intervals (CIs) based on four reference subjects without Canavan disease aged 16 to 36 months (10).”
BackgroundMethodInfluentialSelf-citationDevelopmental and regional distribution of aspartoacylase in rat brain tissue
Bhakoo, K. K., Craig, T. J., & Styles, P. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00561.x · Cited by 77
Matalon, R., Surendran, S., Rady, P. L., Quast, M. J., Campbell, G. A., Matalon, K. M., Tyring, S. K., Wei, J., Peden, C. S., Ezell, E. D. L., et al. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00066-2 · Cited by 77 · cited 1×
“Concurrent studies of native human aspartoacylase in an ASPA knockout mouse model (49) and the ASPA null rat (50) suggested that brain NAA concentrations decrease after treatment with AAV2-ASPA, resulting in behavioral and histopathological improvements, including a decline in seizure frequency.”
BackgroundStructure of aspartoacylase, the brain enzyme impaired in Canavan disease
Bitto, E., Bingman, C. A., Wesenberg, G. E., McCoy, J. G., & Phillips, G. N. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607817104 · Cited by 75 · cited 1×
“Canavan disease is a rare autosomal recessive leukodystrophy caused by mutations in the ASPA gene encoding aspartoacylase (1–3), a zinc carboxypeptidase enzyme (4) that deacetylates N-acetylaspartate (NAA).”
BackgroundCerebral spongy degeneration of infancy
Adornato, B. T., O’Brien, J. S., Lampert, P. W., Roe, T. F., & Neustein, H. B. (1972) · Neurology · doi:10.1212/wnl.22.2.202 · Cited by 73 · cited 1×
“Although classical postmortem studies have shown limited pathology in neurons (38), the prevalence of epilepsy implies abnormal membrane depolarization (41, 42).”
BackgroundTaylor, D. L., Davies, S., Obrenovitch, T. P., Urenjak, J., Richards, D. A., Clark, J. B., & Symon, L. (1994) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1994.62062349.x · Cited by 72 · cited 2×
“It is found throughout the neuronal cytoplasm, dendrites, and axons (19, 20), where it normally forms a steep concentration gradient with respect to the extracellular space (21, 22).”
BackgroundDevelopmental increase of aspartoacylase in oligodendrocytes parallels CNS myelination
Kirmani, B. F., Jacobowitz, D. M., & Namboodiri, M. A. A. (2003) · Developmental Brain Research · doi:10.1016/s0165-3806(02)00592-8 · Cited by 71 · cited 2×
“There is cerebellar and brainstem pathology inCanavan disease, and ASPA is normally expressed in the cerebellar white matter (25, 64).”
BackgroundGambetti, P. L., Mellman, W. J., & Gonatas, N. K. (1969) · Acta Neuropathologica · doi:10.1007/bf00692500 · Cited by 71
Spongy degeneration of the central nervous system (Van Bogaert-Bertrand type?) in a newborn infant
Towfighi, J., Friedman, Z., & Maisels, M. J. (1977) · Acta Neuropathologica · doi:10.1007/bf00686890 · Cited by 66
Zeng, B. J., Wang, Z. H., Ribeiro, L. A., Leone, P., De Gasperi, R., Kim, S. J., Raghavan, S., Ong, E., Pastores, G. M., & Kolodny, E. H. (2002) · Journal of Inherited Metabolic Disease · doi:10.1023/a:1022091223498 · Cited by 64 · cited 1×
“Most ASPA mutations in Canavan disease are functionally equivalent (44) with nearly total loss of enzyme activity, and patients with typical mutations are uniformly severely affected.”
BackgroundSelf-citationKirmani, B. F., Jacobowitz, D. M., Kallarakal, A. T., & Namboodiri, M. A. A. (2002) · Molecular Brain Research · doi:10.1016/s0169-328x(02)00490-4 · Cited by 63 · cited 1×
“There is cerebellar and brainstem pathology inCanavan disease, and ASPA is normally expressed in the cerebellar white matter (25, 64).”
BackgroundYan, H., Ishihara, K., Serikawa, T., & Sasa, M. (2003) · Epilepsia · doi:10.1046/j.1528-1157.2003.49402.x · Cited by 61 · cited 2×
“NAA in extracellular fluid or cerebrospinal fluid (CSF) is associated with seizures in both humans and the tremor rat model of Canavan disease (41, 42).”
BackgroundKlugmann, M., Leichtlein, C. B., Symes, C. W., Serikawa, T., Young, D., & During, M. J. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.01.006 · Cited by 55 · cited 1×
“One notable clinical feature was the relative decrease in seizure frequency in gene therapy– treated subjects, which was also reported in the tremor rat model of Canavan disease after AAV2-ASPA gene therapy (69).”
ResultSelf-citationBaslow, M. H. (1999) · Journal of Inherited Metabolic Disease · doi:10.1023/a:1005437915117 · Cited by 54 · cited 1×
“Evidence to date suggests that the pathological effects of globally elevated NAA in Canavan disease are multifactorial and are related to its diverse physiological roles as an organic osmolyte (21, 27), water cotransporter in metabolically active cells (28), myelin precursor (7, 25, 29–33), intermediate for NAAG (34,…”
BackgroundAstroglia Contain a Specific Transport Mechanism for N‐Acetyl‐l‐Aspartate
Sager, T. N., Thomsen, C., Valsborg, J. S., Laursen, H., & Hansen, A. J. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0730807.x · Cited by 54 · cited 1×
“It is found throughout the neuronal cytoplasm, dendrites, and axons (19, 20), where it normally forms a steep concentration gradient with respect to the extracellular space (21, 22).”
BackgroundA safety trial of high dose glyceryl triacetate for Canavan disease
Segel, R., Anikster, Y., Zevin, S., D, A. S. M., Gahl, W. A., Fisher, D., Staretz‐Chacham, O., Zimran, A., & Altarescu, G. (2011) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2011.03.012 · Cited by 53 · cited 1×
“Lack of bioavailable acetate is unlikely to be the key feature of Canavan disease (72), and proposed acetate supplements (73) may also require reduction in pathologically elevated NAA for any beneficial effect to occur.”
BackgroundEffects of AAV-2-mediated aspartoacylase gene transfer in the tremor rat model of Canavan disease
McPhee, S., Francis, J. S., Janson, C. G., Serikawa, T., Hyland, Κ., Ong, E., Raghavan, S., Freese, A. B., & Leone, P. (2005) · Molecular Brain Research · doi:10.1016/j.molbrainres.2004.12.007 · Cited by 52 · cited 1×
“Concurrent studies of native human aspartoacylase in an ASPA knockout mouse model (49) and the ASPA null rat (50) suggested that brain NAA concentrations decrease after treatment with AAV2-ASPA, resulting in behavioral and histopathological improvements, including a decline in seizure frequency.”
BackgroundSelf-citationEpileptic seizures induced by N-acetyl-l-aspartate in rats: in vivo and in vitro studies
Akimitsu, T., Kurisu, K., Hanaya, R., Iida, K., Kiura, Y., Arita, K., Matsubayashi, H., Ishihara, K., Kitada, K., Serikawa, T., et al. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02028-x · Cited by 52 · cited 1×
“This effect is reproduced by administering high concentrations of NAA to normal rats (68), which suggests that NAA may be excitotoxic in vivo under certain circumstances.”
BackgroundShigematsu, H., Okamura, N., Shimeno, H., Kishimoto, Y., Kan, L., & Fenselau, C. (1983) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1983.tb08052.x · Cited by 48 · cited 1×
“Of special relevance is the fact that aspartoacylase is required for synthesis of cerebronic acid from lignoceric acid (30), which suggests that cerebroside augmentation may thwart dysmyelination.”
BackgroundSpongy degeneration of the brain
Kamoshita, S., Rapin, I., Suzuki, K., & Suzuki, K. (1968) · Neurology · doi:10.1212/wnl.18.10.975 · Cited by 46 · cited 1×
“Chemical analysis in patients with spongy degeneration suggests a relative imbalance in phosphatides and cerebrosides, with low proteolipid and glycolipid levels (71).”
BackgroundNovel role for aspartoacylase in regulation of BDNF and timing of postnatal oligodendrogenesis
Francis, J. S., Olariu, A., McPhee, S. W., & Leone, P. (2006) · Journal of Neuroscience Research · doi:10.1002/jnr.20866 · Cited by 45 · cited 2×
“Evidence to date suggests that the pathological effects of globally elevated NAA in Canavan disease are multifactorial and are related to its diverse physiological roles as an organic osmolyte (21, 27), water cotransporter in metabolically active cells (28), myelin precursor (7, 25, 29–33), intermediate for NAAG (34,…”
BackgroundSelf-citationGlobal CNS gene transfer for a childhood neurogenetic enzyme deficiency: Canavan disease.
Leone, P., Janson, C. G., McPhee, S., & During, M. J. (1999) · PubMed · Cited by 42
Self-citationJanson, C. G., Kolodny, E. H., Zeng, B., Raghavan, S., Pastores, G., Torres, P., Assadi, M., McPhee, S., Goldfarb, O., Saslow, B., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20787 · Cited by 42 · cited 1×
“Recently, a unique mutation that confers an unusually benign phenotype was discovered (52), but this rare variant was not included.”
BackgroundSelf-citationThe effect of N-acetylaspartate on the intracellular free calcium concentration in NTera2-neurons
Rubin, Y., LaPlaca, M. C., Smith, D. H., Thibault, L. E., & Lenkinski, R. E. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)12014-u · Cited by 41 · cited 1×
“The excitotoxic effects of NAA are still poorly understood in vivo and have been recently discounted (65), although NAA and NAAG were reported to activate N-methyl-D-aspartate (NMDA) receptors at millimolar concentrations (66, 67).”
BackgroundAspartoacylase supports oxidative energy metabolism during myelination
Francis, J. S., Strande, L., Markov, V., & Leone, P. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.66 · Cited by 41 · cited 1×
“Lack of bioavailable acetate is unlikely to be the key feature of Canavan disease (72), and proposed acetate supplements (73) may also require reduction in pathologically elevated NAA for any beneficial effect to occur.”
BackgroundSelf-citationMyelin Lipid Abnormalities in the Aspartoacylase-Deficient Tremor Rat
Wang, J., Leone, P., Wu, G., Francis, J. S., Li, H., Jain, M. R., Serikawa, T., & Ledeen, R. W. (2008) · Neurochemical Research · doi:10.1007/s11064-008-9726-5 · Cited by 40 · cited 2×
“These effects probably result from biosynthetic defects in myelin (33) in conjunction with localized periaxonal osmotic effects due to increased NAA.”
BackgroundSelf-citationLithium Citrate for Canavan Disease
Janson, C. G., Assadi, M., Francis, J. S., Bilaniuk, L. T., Shera, D. M., & Leone, P. (2005) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2005.04.015 · Cited by 40 · cited 1×
“At least one subject received lithium for a brief period before gene therapy (55), which was taken into account in the covariates.”
BackgroundSelf-citationN-acetylaspartate : a unique neuronal molecule in the central nervous system
Moffett, J. R. (2006) · DIAL (Catholic University of Leuven) · doi:10.1007/0-387-30172-0 · Cited by 37
Chopra, M., Yao, Y., Blake, T. J. A., Hampson, D. R., & Johnson, E. C. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.152553 · Cited by 36 · cited 1×
“The excitotoxic effects of NAA are still poorly understood in vivo and have been recently discounted (65), although NAA and NAAG were reported to activate N-methyl-D-aspartate (NMDA) receptors at millimolar concentrations (66, 67).”
Background1 H MR spectroscopy of the basal ganglia in childhood: a semiquantitative analysis
Lam, W. W. M., Wang, Z., Zhao, H., Berry, G. T., Kaplan, P. B., Gibson, J., Kaplan, B. S., Bilaniuk, L. T., Hunter, J. V., Haselgrove, J. C., et al. (1998) · Neuroradiology · doi:10.1007/s002340050592 · Cited by 33 · cited 1×
“In previous work (60), we examined a mixed population of normal patients aged 1 to 31 years, looking specifically at the basal ganglia region, and found amean NAA value of 5.”
BackgroundSelf-citationBaslow, M. H., & Guilfoyle, D. N. (2009) · Neurochemical Research · doi:10.1007/s11064-009-9958-z · Cited by 33 · cited 5×
“The excitotoxic effects of NAA are still poorly understood in vivo and have been recently discounted (65), although NAA and NAAG were reported to activate N-methyl-D-aspartate (NMDA) receptors at millimolar concentrations (66, 67).”
BackgroundInfluentialSpongy degeneration of white matter
Sacks, O. W., Brown, W. J., & Aguilar, M. J. (1965) · Neurology · doi:10.1212/wnl.15.2.165 · Cited by 32
Protracted Clinical Course for Patientsd with Canavan Disease
Zelnik, N., LUDER, A. S., Elpeleg, O. N., Gross‐Tsur, V., Amir, N., Hemli, J. A., Fattal, A., & Harel, S. (1993) · Developmental Medicine & Child Neurology · doi:10.1111/j.1469-8749.1993.tb11649.x · Cited by 23 · cited 1×
“Although the natural history of Canavan disease involves increased whole-brain NAA concentrations (10) and progressive disability, prolonged survival to adulthood has been reported as a result of better supportive care (45) including treatment with antiepileptics and othermedications (46), as well as gastric feeding t…”
BackgroundMutation Analysis of the Aspartoacylase Gene in Non-Jewish Patients with Canavan Disease
Zeng, B., Pastores, G. M., Leone, P., Raghavan, S., Wang, Z., Ribeiro, L. A., Torres, P., Ong, E., & Kolodny, E. H. (2006) · Springer eBooks · doi:10.1007/0-387-30172-0_11 · Cited by 18 · cited 2×
“Data were prospectively fit to a generalized linear mixed model, the preferred method for repeated-measures within-subject data, as well as longitudinal cohort data (51).”
MethodSelf-citation
Research works printed but not linked: 2
- Russell D. The Gross Motor Function Measure Manual. Hamilton, Canada: CanChild Centre for Childhood Disability Research, McMaster University; 1993. [Google Scholar]
- Mullen EM. The Mullen Scales of Early Learning. Circle Pines, MN: American Guidance Service; 1995. [Google Scholar]
Cited by
Gene therapy returns to centre stage
Naldini, L. (2015) · Nature · doi:10.1038/nature15818 · Cited by 1,184
Engineering adeno-associated virus vectors for gene therapy
Li, C., & Samulski, R. J. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-019-0205-4 · Cited by 1,175
Self-citationImmune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955
“Delivery of small amounts of AAV vectors directly into the brain has been tested in a number of trials for Parkinson disease, 13,51,52,107 Canavan disease, 14,108 and late infantile neuronal ceroid lipofuscinosis.”
Adeno-associated virus as a delivery vector for gene therapy of human diseases
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01780-w · Cited by 904
Current clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743
“The reversal of biochemical and structural biomarkers suggests that the process is reversible; however, earlier intervention is suspected to lead to a more robust clinical response.(54) New technologies using AAV-ASPA targeting oligodendrocytes are now being studied.”
BackgroundInfluential
Metadata
- Authors
- Leone, P., Shera, D., McPhee, S. W. J., Francis, J. S., Kolodny, E. H., Bilaniuk, L. T., Wang, D.-J., Assadi, M., Goldfarb, O., Goldman, H. W., Freese, A., Young, D., During, M. J., Samulski, R. J., & Janson, C. G.
- Affiliations
- University of Medicine and Dentistry of New Jersey (US)
- Children's Hospital of Philadelphia (US)
- AskBio (United States) (US)
- NYU Langone Health (US)
- Cooper University Hospital (US)
- University of Minnesota (US)
- University of Auckland (NZ)
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Leone, Paola
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2012-12-19
- Volume
- 4
- Issue
- 165
- Pages
- 165ra163-165ra163
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC3794457
- OpenAlex
- W2119934328
- Cited by
- 307
- References
- 75
- Citations by year
- 2026: 7 · 2025: 18 · 2024: 53 · 2023: 23 · 2022: 14 · 2021: 24 · 2020: 21 · 2019: 17 · 2018: 24 · 2017: 24 · 2016: 21 · 2015: 22 · 2014: 24 · 2013: 15
- FWCI
- 11.76
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- Canavan Research Foundation
- National Institutes of Health
- National Institute of Neurological Disorders and Stroke (R01NS044576, R01-NS42120, R01NS042120)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Keywords
- Canavan disease, gene therapy, aspartoacylase, leukodystrophy, N-acetylaspartate, adeno-associated virus vectors, long-term safety, brain atrophy, seizure frequency, clinical outcomes
- MeSH terms
- Aspartic Acid, Brain, Child, Child, Preschool, Humans, Infant, Prospective Studies, Genetic Therapy, Canavan Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.